Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...